A crossover study comparing gabapentin and fluoxetine for the treatment of vasomotor symptoms among postmenopausal women

被引:9
|
作者
Rahmanian, Mojgan [1 ]
Mohseni, Arash [1 ]
Ghorbani, Raheb [2 ]
机构
[1] Semnan Univ Med Sci, Res Ctr Abnormal Uterine Bleeding, Semnan 351989951, Iran
[2] Semnan Univ Med Sci, Fac Med, Dept Community Med, Res Ctr Social Determinants Hlth, Semnan 351989951, Iran
关键词
Fluoxetine; Gabapentin; Hot flash; Night sweats; Vasomotor symptoms; MENOPAUSAL HOT FLASHES; BREAST-CANCER; ESTROGEN; PLACEBO; MANAGEMENT;
D O I
10.1016/j.ijgo.2015.04.042
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To compare the effectiveness of fluoxetine and gabapentin for treatment of vasomotor symptoms (VMS) after the menopause. Methods: Between March 2011 and March 2012, a randomized crossover study was performed at a center in Semnan, Iran, among postmenopausal women aged 45-57 years with hot flashes (>= 2 per day for previous 4 months) for which they had received no previous treatment. Participants were divided into two groups with consecutive numbers assigned in order of recruitment. In the first treatment round (4 weeks), group A received 20 mg/day fluoxetine and group B received 300 mg/day gabapentin. After a 2-week washout period, group A received gabapentin and group B received fluoxetine in a second round (4 weeks). Information about VMS was obtained with the Greene Climacteric Scale questionnaire. Participants and all investigators except one were masked to group assignment. Results: Data for 79 participants (39 in group A, 40 in group B) were analyzed. In both treatment rounds, gabapentin caused greater reductions in the severity of hot flashes than did fluoxetine (P < 0.001 for both). After the first round of treatment those who had received gabapentin reported greater reductions in the severity of night sweats (P < 0.001). Conclusion: Gabapentin at a dose of 300 mg/day is more effective for treatment of VMS among postmenopausal women than is 20 mg/day fluoxetine. (C) 2015 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:87 / 90
页数:4
相关论文
共 50 条
  • [21] The comparison of isoflavone to estrogen effects on the vasomotor symptoms of postmenopausal women
    Kaari, C
    Haidar, MA
    Patriarca, MT
    Soares, JM
    Costa, AMM
    Han, KH
    de Lima, GR
    Fernandes, CE
    Baracat, EC
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2003, 10 (06): : 598 - 598
  • [22] The Association between Vasomotor Symptoms and Hemostatic Factors in Postmenopausal Women
    Harrington, Laura B.
    Rossouw, Jacques E.
    Cushman, Mary
    Blondon, Marc
    Kaunitz, Andrew M.
    McKnight, Barbara
    Heckbert, Susan R.
    Woods, Nancy F.
    LaCroix, Andrea Z.
    Allison, Matthew A.
    Martin, Lisa W.
    Johnson, Karen C.
    Smith, Nicholas L.
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2014, 21 (12): : 1367 - 1367
  • [23] Relationship between vasomotor symptoms and metabolic syndrome in postmenopausal women
    Sayan, Sena
    Pekin, Tanju
    Yildizhan, Begum
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2018, 46 (10) : 4157 - 4166
  • [24] Vasomotor symptoms and the risk of incident venous thrombosis in postmenopausal women
    Harrington, L. B.
    Blondon, M.
    Cushman, M.
    Kaunitz, A. M.
    Allison, M. A.
    Wang, L.
    Sullivan, S.
    Woods, N. F.
    LaCroix, A. Z.
    Heckbert, S. R.
    McKnight, B.
    Rossouw, J.
    Smith, N. L.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2018, 16 (05) : 886 - 892
  • [25] Longitudinal association of vasomotor symptoms and psychosocial outcomes among postmenopausal women in the United States: a population-based study
    Van Dole, Kristen B.
    Williams, Rachel E.
    Brown, Rebekkah S.
    Gaynes, Bradley
    DeVellis, Robert
    Funk, Michele Jonsson
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2010, 17 (05): : 917 - 923
  • [26] Vasomotor symptoms are not associated with reduced bone mass in postmenopausal women:: The Rancho Bernardo Study
    von Mühlen, DG
    Soroko, S
    Kritz-Silverstein, D
    Barrett-Connor, E
    JOURNAL OF WOMENS HEALTH & GENDER-BASED MEDICINE, 2000, 9 (05): : 505 - 511
  • [27] Influence of the CYP17 polymorphism on vasomotor symptoms in postmenopausal women: a pilot study
    Nogueira, R. C., Jr.
    Massad Costa, A. M.
    Silva, I. D. C. G.
    Valleta Carvalho, C.
    Maganhin, C.
    Baracat, E. C.
    Soares, J. M., Jr.
    CLIMACTERIC, 2011, 14 (05) : 537 - 543
  • [28] Efficacy and safety of Evamist™, a new transdermal estradiol spray, in treatment of vasomotor symptoms in postmenopausal women
    Buster, John
    Day, Wesley W.
    Peterson, Craig
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2007, 14 (06): : 1084 - 1084
  • [29] Steady-State Pharmacokinetics of Gabapentin after Administration of a Novel Gastroretentive Extended-Release Formulation in Postmenopausal Women with Vasomotor Symptoms
    Cowles, Verne E.
    Gordi, Toufigh
    Hou, Sui Yuen Eddie
    CLINICAL DRUG INVESTIGATION, 2012, 32 (09) : 593 - 601
  • [30] Is heart rate variability associated with frequency and intensity of vasomotor symptoms among healthy perimenopausal and postmenopausal women?
    Jones, Salene M. W.
    Guthrie, Katherine A.
    LaCroix, Andrea Z.
    Sternfeld, Barbara
    Landis, Carol A.
    Reed, Susan D.
    Dunn, Andrea
    Caan, Bette
    Cohen, Lee S.
    Hunt, Julie
    Newton, Katherine M.
    CLINICAL AUTONOMIC RESEARCH, 2016, 26 (01) : 7 - 13